Business Context and Reporting Period
This Form 6-K filing by Alterity Therapeutics Limited, a development stage enterprise, covers the month of October 2024. The report was filed on October 4, 2024, and is incorporated by reference into the company's Registration Statements on Form S-8 and Form F-3.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise reporting a specific corporate event, this document does not contain financial statements.
Material Changes
The primary material change disclosed in this filing is a Change of Share Registry, submitted as Exhibit 99.1.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the administrative update regarding the share registry.
Investor Verification Checklist
- Verify the details of the Change of Share Registry in Exhibit 99.1.
- Confirm the impact of the registry change on shareholder records and communication protocols.
- Review the referenced Registration Statements (Form S-8 and Form F-3) for broader corporate context.